NAI, VAI, OAI sort the inspection, not the firm

The three labels answer a narrower question than 'how did it go'

No Action Indicated means the inspection found the site in an acceptable state of compliance, and usually closed without a Form 483 at all. Voluntary Action Indicated means the inspection did turn up objectionable conditions — almost always documented on a 483 — but FDA has judged the firm capable of correcting them on its own, without the agency recommending further action. Official Action Indicated means the violations found were significant enough that FDA intends to act: a Warning Letter, an import alert, or, in the more serious cases, a consent decree. The three categories aren't a report card running from good to bad in even steps — NAI and VAI both mean the agency is leaving the fix to the firm; OAI is the one line where that stops being true.

A 483 doesn't decide its own classification

Getting a Form 483 doesn't put a firm on a fixed track toward VAI or OAI, and finishing an inspection without one doesn't guarantee NAI either — the form documents what an investigator observed during the visit, not what the agency will eventually conclude about it. Two establishments can walk away with similarly worded 483s covering similar findings and land on different classifications, because what separates VAI from OAI isn't the list of observations so much as their severity, their pattern across the firm's history, and how convincingly the firm's own response addresses them. This blog has already covered the 15-business-day window a firm has to answer a 483 in writing, and that response isn't a courtesy filed alongside the inspection record — it's evidence the classification decision actually weighs.

The classification happens after the visit, not during it

The investigator who conducts the inspection doesn't issue the final classification on site. That determination comes out of a review conducted after the visit closes, one that reads the establishment inspection report the investigator wrote, the Form 483 if one was issued, and the firm's own written response when one was submitted before the review happened — weighing all three together rather than treating the 483's observations as a self-executing verdict. A firm that skips its written response, or files one late enough to miss the review, hasn't avoided a chance to shape the outcome — it's left the decision to be made on the inspection record alone, without the context a timely response could have added.

The classification outlives the visit that produced it

Once assigned, an inspection's classification becomes part of the public record FDA keeps on that establishment, visible in the agency's own inspection classification database alongside the site's inspection history going back years. A pattern of repeated VAI findings on the same subject — the same clause, the same process — reads differently to an investigator walking in for the next inspection than a single isolated finding does, even though neither individual classification technically escalates on its own. A firm tracking its own compliance posture by counting open CAPAs is missing the record an outside reviewer, or the next inspector, will actually open first.

Where this meets the file

The gap between how the EU and the US handle this moment is worth noticing on its own: a notified body's unannounced audit under MDR Annex IX can flag nonconformities on the spot, but an FDA inspection's actual classification is a separate, after-the-fact decision a firm can still influence with a well-built response. An inspection-response tracker that keeps the 483 response, its submission date, and the resulting classification as linked but distinct records — rather than treating the response as filed-and-forgotten once it's sent — is previewed in the launch catalog. If your program tracks this differently, the shelf takes that correction directly.